• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Public Health

Effectiveness of medical device postapproval surveillance unclear

byShayna BejaimalandJames Jiang
September 30, 2014
in Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The effectiveness of the present FDA-mandated postapproval study program is unclear, due in large part to variability in characteristics of individual postapproval studies.

2. The postapproval study program has resulted mainly in FDA requests for device label changes; the impact of these changes on physician and patient decisions is unclear.

Evidence Rating Level: 2 (Good)

Study Rundown: High-risk medical devices often undergo fewer premarket clinical trials than pharmaceuticals; thus it is important to study postmarket safety and efficacy to ensure patient protection. The US Food and Drug Administration (FDA) has implemented a strategic plan for postmarket surveillance of medical devices that includes FDA-mandated postapproval studies (PAS). The goal of PAS is to “gather specific information to address questions about the postmarket performance of or experience with an approved medical device,” which has the potential to result in medical device withdrawal from the market. This study sought to examine the characteristics and information accessibility of PAS, and to assess the overall effectiveness of the FDA’s PAS program.

This descriptive study found that there were variable details on reasons for the ordered PAS, the studies’ hypotheses or end points, and the causes for PAS implementation delay. The FDA mandate states that if the manufacturer does not comply satisfactorily with PAS requirements, warning letters, monetary penalties or device approval withdrawal could be initiated. However, the FDA has never issued any such penalties. This study was the first to analyze the quality of the FDA’s PAS program. However due to the inconsistency in information available from the FDA, the study was unable to draw conclusions on the effect of the studies. Further collaboration with stakeholders will help to ensure that PAS are effectively improving public health.

Click to read the study, published today in JAMA Internal Medicine

RELATED REPORTS

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

Food and Drug Administration to Fully Integrate Generative Artificial Intelligence by June

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [May 23rd, 2025]

Click to read an invited commentary in JAMA Internal Medicine

Click to read an editorial published in JAMA Internal Medicine

Relevant Reading: Left to their own devices: Breakdowns in United States medical premarket review

In-Depth [descriptive study]: This study used the publicly available FDA PAS website to abstract information on all 223 PAS done between 2005 and 2011. The website contained information on device names, study characteristics and statuses of manufacturer reports to the FDA on PAS programs. It also contained information on which approval track each device used to enter the market. Approximately 48% of all premarket approval applications had PAS. The author-assigned PAS study designs included prospective cohorts (49%), follow-up (27%), randomized controlled trials (3%) and others. PAS could also be mixed methods (e.g., prospective cohort and follow-up). Study progress was depicted on the FDA website with general status labels (completed, progress adequate, progress inadequate, study pending, other, terminated), however no further detail on specific reasons for inadequately progressing PAS was available.

There were 58 completed studies, 93% of which included in-depth information on patient enrollment, follow-up rates and safety and effectiveness findings. There was a median delay of 6 months for 37% of all PAS. The PAS were used by the FDA to address specific concerns about safety and efficacy and thus had small sample sizes with an average of 350. Of the completed PAS, 53% resulted in requests for device labeling changes, which was the most common result of a PAS. However, it is unclear if these label changes influence physician and patient decisions. One device was removed from the market due to adverse events that were identified in the PAS.

More from this author: Device-guided breathing not associated with improved blood pressure control, Arterial catheter monitoring in ICU not associated with mortality benefit, Overall US diet quality improved from 1999 to 2010

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: deviceFDAhealth policy
Previous Post

Ixekizumab may be safe and effective for chronic plaque psoriasis

Next Post

2 Minute Medicine Rewind September 22 – September 29, 2014

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025
FDA-regulated clinical trials rarely report violations
AI Roundup

Food and Drug Administration to Fully Integrate Generative Artificial Intelligence by June

May 26, 2025
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [May 23rd, 2025]

May 23, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Pharma

FDA Approves Dupilumab for Chronic Spontaneous Urticaria

May 14, 2025
Next Post
Ebola outbreak projected to exceed 20,000 cases by November

2 Minute Medicine Rewind September 22 – September 29, 2014

Phase III trial shows survival benefit for early multiple myeloma

Glatiramer acetate (Copaxone) therapy may alter B cell function in multiple sclerosis

Esmolol-induced heart rate reduction may aid in septic shock

Simvastatin ineffective in acute respiratory distress syndrome [HARP-2 trial]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.